ReviewSeminars in dialysis
A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.
Review in Seminars in dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- A systematically collated library of prescribing safety indicators for people with chronic kidney disease.BMC nephrology · 2020Pooled it
- Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency.Clinical and translational science · 2024Trial
- Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian.Clinical pharmacokinetics · 2024Trial
- Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.Diabetes, obesity & metabolism · 2026Article
- Sexual Dimorphism in Cardiometabolic Diseases: From Development to Senescence and Therapeutic Approaches.Cells · 2025Review
- Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions.Journal of the American Society of Nephrology : JASN · 2025Review
- Unveiling the role of sex in the metabolism of indoxyl sulfate and apixaban.Scientific reports · 2025Article
- Development and Validation of an Improved HPLC-MS/MS Method for Quantifying Total and Unbound Lenalidomide in Human Plasma.Pharmaceutics · 2024Article
- Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.Journal of clinical medicine · 2024Article
- De-indexed estimated glomerular filtration rates for the dosing of oral antidiabetic drugs in patients with chronic kidney disease.Frontiers in pharmacology · 2024Article
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development.Clinical pharmacokinetics · 2023Article
- Pattern, frequency and factors associated with inappropriate high dosing in chronic kidney disease patients at a tertiary care hospital in Pakistan.BMC nephrology · 2023Article
- Anticancer drug therapy for patients with renal dysfunction.International journal of clinical oncology · 2023Review
- Structure and Function of a Provincial Renal Pharmacy Program: Applying the Chronic Care Model to Address Equitable Access to Medication and Pharmacy Services.Canadian journal of kidney health and disease · 2023Article
- The Impact of Suboptimal 25-Hydroxyvitamin D Levels and Cholecalciferol Replacement on the Pharmacokinetics of Oral Midazolam in Control Subjects and Patients With Chronic Kidney Disease.Journal of clinical pharmacology · 2022Article
- In-Hospital Prescription Checking System for Hospitalized Patients with Decreased Glomerular Filtration Rate.Kidney360 · 2022Article
- Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin.Journal of clinical pharmacology · 2022Article
- Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure.Current cardiology reports · 2021Review
- Pharmacokinetics in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2020Review
- Pharmacotherapeutic Management of Neuropathic Pain in End-Stage Renal Disease.Kidney diseases (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Unrecognized alterations in pharmacokinetics, which quantitatively describes the time course of drug disposition in the body, may lead to clinically significant changes in systemic exposure and corresponding response to drugs in patients with chronic kidney disease (CKD). Clinicians must take pharmacokinetic changes into consideration when selecting and dosing medications in CKD patients to optimize the risk:benefit ratio. Pharmacokinetic changes in absorption, distribution, and renal clearance are well characterized and generally predictable for most drugs. Conversely, changes in nonrenal clearance are less well understood and corresponding clinical implications are still being elucidated. This review provides a synopsis of alterations in each of these pharmacokinetic parameters observed in patients with advanced CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.